EN | RU
EN | RU

Help Support

Back

Research finds long-term efficacy of baricitinib in moderate to severe atopic dermatitis

Research finds long-term efficacy of baricitinib in moderate to severe atopic dermatitis Research finds long-term efficacy of baricitinib in moderate to severe atopic dermatitis
Research finds long-term efficacy of baricitinib in moderate to severe atopic dermatitis Research finds long-term efficacy of baricitinib in moderate to severe atopic dermatitis

What's new?

Baricitinib 2 mg or 4 mg was found to have a long-term efficacy in relieving atopic dermatitis.

As per the outcomes of an extension study (BREEZE-AD3) of two randomized clinical trials (BREEZE-AD1 and BREEZE-AD2) issued in JAMA Dermatology, the use of baricitinib (an oral selective Janus kinase inhibitor) dosed at 2 mg and 4 mg offered long-term efficacy (up to 68 weeks) in adults with atopic dermatitis. To determine baricitinib’s long-term efficacy, Jonathan I Silverberg and colleagues recruited moderate to severe atopic dermatitis patients with a therapy response or incomplete response in the two studies.

The percentage of subjects with a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score of 0 for clear,1 for almost clear, or 2 for mild, at different time points i.e. weeks 16, 36, and 52 was the primary outcome. People with a 4-point or more score in the itch numeric rating scale (NRS) and at least 75% or higher score in the Eczema Area and Severity Index (EASI75) were the secondary outcomes.

Of the responder/partial responder population, the percentage of patients treated with baricitinib 4 mg (70 patients) and baricitinib 2 mg dose (54 patients) and achieving vIGA-AD score (0,1) and at least 75% or higher improvement in the EASI score at 16 and 68 weeks is depicted in table 1:


The percentage of participants attaining an itch NRS improvement more than or equal to four points at week 16 and week 32 is shown in table 2:


Thus, baricitinib exhibits a long-term efficacy in atopic dermatitis patients and may be considered as a longer-term therapeutic option for such patients. 

Source:

JAMA Dermatology

Article:

Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials

Authors:

Jonathan I Silverberg et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: